Financial Performance - Total revenue for Q2 fiscal 2025 was $13.5 million, a 17% increase from $11.6 million in Q2 fiscal 2024[7] - Adjusted EBITDA for Q2 fiscal 2025 was $1.1 million, compared to an adjusted EBITDA loss of $1.4 million in Q2 fiscal 2024[8] - Gross profit for Q2 fiscal 2025 was $6.1 million, with a margin of 45%, up from a margin of 43% in Q2 fiscal 2024[9] - For the first half of fiscal 2025, total revenue increased 14.2% to $27.6 million compared to $24.1 million in the same period last year[15] - The company projects revenue growth for the year of at least 10% to 15%[6] - Oncology services revenue for the three months ended October 31, 2024, was $13.489 million, a 16.6% increase from $11.573 million for the same period in 2023[27] - Net income for the six months ended October 31, 2024, was $2.041 million, compared to a net loss of $4.637 million for the same period in 2023[27] - The company reported a basic net income per share of $0.05 for the three months ended October 31, 2024, compared to a loss of $0.15 per share for the same period in 2023[27] Expenses and Costs - Research and development expenses for Q2 fiscal 2025 decreased by 32.8% to $1.7 million compared to $2.5 million in Q2 fiscal 2024[10] - Total costs and operating expenses for Q2 fiscal 2025 were $12.8 million, a decrease of 5.7% from $13.5 million in Q2 fiscal 2024[7] - Cost of oncology services for Q2 fiscal 2025 was $7.4 million, an increase of 12.2% from $6.6 million in Q2 fiscal 2024[9] - Research and development expenses for the three months ended October 31, 2024, were $1.689 million, down from $2.515 million for the same period in 2023[27] Assets and Liabilities - Total current assets increased to $14.084 million as of October 31, 2024, from $13.639 million as of April 30, 2024[28] - Total liabilities decreased to $24.559 million as of October 31, 2024, from $28.035 million as of April 30, 2024[28] - Cash and cash equivalents increased to $2.754 million as of October 31, 2024, from $2.618 million as of April 30, 2024[28] - Deferred revenue decreased to $10.220 million as of October 31, 2024, from $12.094 million as of April 30, 2024[28] Cash Flow - The company ended the quarter with cash on hand of approximately $2.8 million and no debt[14] - Net cash provided by operating activities for the six months ended October 31, 2024, was $28, compared to a net cash used of $3.402 million for the same period in 2023[29] Share Information - The weighted average common shares outstanding for the three months ended October 31, 2024, was 13,593,766, compared to 13,497,061 for the same period in 2023[27]
Champions Oncology(CSBR) - 2025 Q2 - Quarterly Results